drug_type
RELEVANT_DRUG
intervention_type
Drug (monoclonal antibody)
drug_description
Humanized, afucosylated IgG1 monoclonal antibody that antagonizes the OX40 (CD134) costimulatory receptor and can deplete OX40+ activated T cells via ADCC, reducing T-cell activation, survival, memory, and type 2 inflammation relevant to atopic dermatitis. Administered as a single subcutaneous dose (via vial or prefilled syringe).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Monoclonal Antibodies, Humanized
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized, afucosylated IgG1 monoclonal antibody against OX40 (CD134) that blocks OX40–OX40L costimulatory signaling and, via enhanced Fc-mediated ADCC, depletes OX40+ activated T cells, thereby reducing T‑cell activation, survival/memory, and type 2 inflammatory responses.
drug_name
Rocatinlimab (AMG 451)
nct_id_drug_ref
NCT06268860